Hong-Li Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hong-Li Liu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Jian Liu
Gynecological Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu City 233004, Anhui Province, China
1 shared publicationJing Liu
Gynecological Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu City 233004, Anhui Province, China
1 shared publicationSheng-Ze Li
Gynecological Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu City 233004, Anhui Province, China
1 shared publicationSu-Yang Guo
Gynecological Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu City 233004, Anhui Province, China
1 shared publication
Latest Publications
- Open Access
- 1 February 2017
- Published by Medknow in Asian Pacific Journal of Tropical Medicine
- Vol. 10 (2) , 184-188
HSP70 inhibitor combined with cisplatin suppresses the cervical cancer proliferation in vitro and transplanted tumor growth: An experimental study
To study the regulating effect of HSP70 inhibitor (PES) combined with cisplatin on cervical cancer proliferation in vitro and transplanted tumor growth. Cervical cancer Hela cell lines were cultured and divided into control group, cisplatin group, PES group and cisplatin + PES group that were treated with serum-free DMEM, cisplatin with final concentration of 10 μmol/L, PES 20 μmol/L and cisplatin 10 μmol/L combined with PES with 20 μmol/L, respectively; animal models with cervical cancer xenografts were established and divided into control group, cisplatin group, PES group and cisplatin + PES group who received intra-tumor injection of normal saline, 10 μmol/L cisplatin, 20 μmol/L PES as well as 10 μmol/L cisplatin + 20 μmol/L PES, respectively. Cell proliferation activity, transplanted tumor volume and mitochondria apoptosis molecule expression were detected. Cell viability value and Bcl-2 mRNA expression in cells of cisplatin group, PES group and cisplatin + PES group were significantly lower than those of control group while Bax, Caspase-3 and Caspase-9 mRNA expression in cells were significantly higher than those of control group; transplanted tumor volume and the Bcl-2 mRNA expression in transplanted tumor tissue of cisplatin group, PES group and cisplatin + PES group were significantly lower than those of control group while Bax, Caspase-3 and Caspase-9 mRNA expression in transplanted tumor tissue were significantly higher than those of control group. HSP70 inhibitor combined with cisplatin can inhibit cervical cancer cell proliferation in vitro and transplanted tumor growth through mitochondrial apoptosis pathway.
- 1 February 2017
- Published by Medknow in Asian Pacific Journal of Tropical Medicine
- Vol. 10 (2) , 184-188
Open AccessHSP70 inhibitor combined with cisplatin suppresses the cervical cancer proliferation in vitro and transplanted tumor growth: An experimental study
To study the regulating effect of HSP70 inhibitor (PES) combined with cisplatin on cervical cancer proliferation in vitro and transplanted tumor growth. Cervical cancer Hela cell lines were cultured and divided into control group, cisplatin group, PES group and cisplatin + PES group that were treated with serum-free DMEM, cisplatin with final concentration of 10 μmol/L, PES 20 μmol/L and cisplatin 10 μmol/L combined with PES with 20 μmol/L, respectively; animal models with cervical cancer xenografts were established and divided into control group, cisplatin group, PES group and cisplatin + PES group who received intra-tumor injection of normal saline, 10 μmol/L cisplatin, 20 μmol/L PES as well as 10 μmol/L cisplatin + 20 μmol/L PES, respectively. Cell proliferation activity, transplanted tumor volume and mitochondria apoptosis molecule expression were detected. Cell viability value and Bcl-2 mRNA expression in cells of cisplatin group, PES group and cisplatin + PES group were significantly lower than those of control group while Bax, Caspase-3 and Caspase-9 mRNA expression in cells were significantly higher than those of control group; transplanted tumor volume and the Bcl-2 mRNA expression in transplanted tumor tissue of cisplatin group, PES group and cisplatin + PES group were significantly lower than those of control group while Bax, Caspase-3 and Caspase-9 mRNA expression in transplanted tumor tissue were significantly higher than those of control group. HSP70 inhibitor combined with cisplatin can inhibit cervical cancer cell proliferation in vitro and transplanted tumor growth through mitochondrial apoptosis pathway.